Geode Capital Management LLC Increases Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Geode Capital Management LLC increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 2.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,389,240 shares of the company’s stock after buying an additional 45,930 shares during the quarter. Geode Capital Management LLC owned about 2.35% of Intellia Therapeutics worth $27,865,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of NTLA. Whipplewood Advisors LLC purchased a new stake in Intellia Therapeutics in the fourth quarter valued at $40,000. Jones Financial Companies Lllp grew its position in Intellia Therapeutics by 140.9% during the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock valued at $45,000 after buying an additional 2,280 shares during the period. Daiwa Securities Group Inc. increased its holdings in Intellia Therapeutics by 80.6% in the fourth quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company’s stock valued at $60,000 after buying an additional 2,299 shares in the last quarter. KBC Group NV raised its position in shares of Intellia Therapeutics by 62.4% in the fourth quarter. KBC Group NV now owns 6,093 shares of the company’s stock worth $71,000 after acquiring an additional 2,340 shares during the period. Finally, AdvisorNet Financial Inc boosted its stake in shares of Intellia Therapeutics by 96.4% during the 4th quarter. AdvisorNet Financial Inc now owns 10,085 shares of the company’s stock worth $118,000 after acquiring an additional 4,950 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Chardan Capital dropped their price objective on Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating on the stock in a report on Friday, February 28th. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research note on Monday, March 3rd. HC Wainwright assumed coverage on shares of Intellia Therapeutics in a research report on Wednesday, March 5th. They set a “buy” rating and a $30.00 price target for the company. Truist Financial decreased their price objective on shares of Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th. Finally, Wedbush reiterated a “neutral” rating and issued a $10.00 target price (down previously from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $37.56.

Intellia Therapeutics Stock Up 5.4 %

NASDAQ:NTLA opened at $7.23 on Friday. Intellia Therapeutics, Inc. has a 52-week low of $5.90 and a 52-week high of $28.18. The stock’s 50 day moving average price is $8.93 and its 200 day moving average price is $12.28. The company has a market capitalization of $748.43 million, a PE ratio of -1.33 and a beta of 2.23.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.